Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heregulins implicated in cellular functions other than receptor activation.

Madlaina Breuleux1, Fabrice Schoumacher, Daniel Rehn

  • 1Novartis Pharma AG, Klybeckstrasse 125, WKL-125.12.59, 4002 Basel, Switzerland. madlaina.breuleux@novartis.com

Molecular Cancer Research : MCR
|February 1, 2006
PubMed
Summary

Heregulins (HRG) translocate to the nucleus in breast cancer cells, interacting with nuclear factors and repressing transcription. This reveals novel nuclear functions for HRG beyond ErbB receptor signaling.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International collaboration generates high quality clusters of pharmaceutical patents.

Pharmaceutical patent analyst·2019
Same author

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Haematologica·2016
Same author

Biotech patent landscapes: a reflection of global innovation?

Pharmaceutical patent analyst·2015
Same author

Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor.

Cancers·2013
Same author

Therapeutic nanoparticles in clinics and under clinical evaluation.

Nanomedicine (London, England)·2013
Same author

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Journal of drug targeting·2012

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Heregulins (HRG) are secreted growth factors activating ErbB receptors, influencing cell growth and metastasis.
  • Previous research indicated some HRG1 splice variants enter the cell nucleus.

Purpose of the Study:

  • To investigate the nuclear localization and function of HRGalpha(1-241) in breast cancer cells.
  • To identify the molecular mechanisms underlying HRG's nuclear translocation and potential nuclear roles.

Main Methods:

  • Investigated subcellular localization of HRGalpha(1-241) using breast cancer cells.
  • Screened a mammary gland cDNA library with HRGalpha using a yeast two-hybrid system.
  • Performed co-immunoprecipitation of endogenous HRG and reporter gene assays.

Related Experiment Videos

Main Results:

  • HRGalpha(1-241) translocated to the nucleus, accumulating in dot-like structures, dependent on specific nuclear localization sequences and domains.
  • HRGalpha(1-241) interacted with nuclear factors, including histone deacetylase 2, involved in transcriptional control.
  • HRGalpha(1-241) demonstrated transcriptional repression activity and potential for homodimerization.

Conclusions:

  • HRG1 splice variants possess multifunctional properties, including nuclear regulatory functions distinct from ErbB receptor signaling.
  • HRG's nuclear actions involve transcriptional repression and interactions with nuclear proteins, suggesting novel roles in cancer biology.